

Level 2, 66 Hunter Street  
Sydney NSW 2000  
Tel: (61-2) 9300 3344  
Fax: (61-2) 9221 6333

E-mail: [mmora@miscorp.com.au](mailto:mmora@miscorp.com.au)  
Website: [www.biotron.com.au](http://www.biotron.com.au)

29 January 2026

The Manager Companies  
ASX Limited  
20 Bridge Street  
Sydney NSW 2000

(8 pages by email)

Dear Madam

## **REPORT ON ACTIVITIES FOR THE QUARTER ENDED 31 DECEMBER 2025**

During the quarter ended 31 December 2025 Biotron Limited ('Biotron' or 'the Company') achieved the following:

- Announced the acquisition of Sedarex Limited (Sedarex) and a \$2.5M capital raising.
- Completed a two-tranche Placement raising \$1 million (before costs).
- Completed an Entitlement offer raising \$645,861 (before costs).
- Completed the acquisition of 100% of Sedarex.
- Appointed Dr Paul Kasian as Non-Executive Director.
- Completed an assessment of Biotron's lead compound for Hepatitis B virus (HBV) in two animal models of HBV infection as well as additional cell-based infectivity studies:
  - BIT-HBV001, Biotron's lead HBV drug, shows anti-HBV activity in two different mouse models of HBV infection,
  - BIT-HBV001 shows superior anti-HBV activity to Tenofovir, the first-line treatment for HBV, against specific replication markers in *in vitro*, cell-based assays of HBV infection,
  - BIT-HBV001 improves the anti-HBV activity of Tenofovir when used in combination in an *in vitro*, cell-based combination (synergism) study with Tenofovir,
- Filing of a patent application relating to a series of novel, undisclosed small molecule compounds, including BIT-HBV001, for treatment of serious viral infections including HBV.

In October 2025 the Company announced the acquisition of Sedarex Limited (Sedarex) and a \$2.5M capital raising.

Following receipt of shareholder approval at the Annual General Meeting (AGM) held on 17 November 2025 Biotron completed acquisition of Sedarex on 10 December 2025.

Sedarex, a public unlisted company, which holds global patents for SedRx™, a safer, next-generation general anaesthetic. SedRx contains alfaxalone which is the active ingredient (API) of a proven general anesthesia Althesin that was marketed in Europe for 14 years and had 50% share of the day care market in the UK.

SedRx eliminates past safety risks associated with Althesin and maintains cognitive abilities post-anaesthetic procedure. This new formulation has proven superior safety and cognitive outcomes versus leading anaesthetics in Phase 1 and pilot Phase 2a studies, with FDA backing for a 505(b)(2) pathway and potential EMA abridged approval.

In addition to the late-stage general anaesthetic opportunity offered by SedRx, Sedarex has additional new indications in the high growth neuroscientific field under development.

The transaction was supported by a \$1m Placement led by Peak Asset Management, with a 2 tranche placement at an issue price of \$0.003 per share, with 1 attaching option (\$0.02 expiring 2 years from issue) for every 2 shares issued. The first tranche was completed on 22 October 2025, raising \$597,260 before costs, and the second tranche was completed on 2 December 2025 raising \$402,740 before costs.

Following receipt of shareholder approval for the acquisition of Sedarex at the AGM, Biotron initiated a rights issue to Biotron shareholders to raise a further ~\$1.5 million on the same terms as the Placement. The rights issue raised \$645,861. The Company has a commitment from Peak Asset Management to subscribe for any shortfall under the Rights Issue. The last date to issue shortfall shares is 12 March 2026.

During the quarter the Company provided an update on its Hepatitis B virus (HBV) program. The results of studies in two animal models of HBV infection confirmed the antiviral activity of BIT-HBV001, Biotron's lead HBV compound. A series of follow-up cell-based infectivity studies were conducted, which demonstrated that BIT-HBV001 strongly inhibited a set of five HBV replication end points. This was in contrast to Tenofovir, the current first-line treatment for HBV, which had good activity against only one HBV replication end point.

The results of these HBV studies indicate that Biotron's HBV approach has advantages over the current standard of care treatment for HBV. A patent has been filed for BIT-HBV001 and associated compounds, for their composition (structures), method of manufacture, and use.

Other R&D expenditure during the quarter includes ongoing costs associated with maintaining the Company's broad patent portfolio, which underpins and protects the intellectual property that has been developed to date, as well as ongoing maintenance and other activities associated with retention and storage of samples from clinical studies, the Company's compound library and clinical grade drug product.

In parallel with the above the Company is continuing its commercialisation activities in collaboration with the US-based C14 Consulting Group.


On 23 December 2025 the Company appointed Dr Paul Kasian as Non-Executive Director.

## Expenditure

As disclosed in the Company's Quarterly Cash Flow Report, expenditure on research and development activities during the quarter totaled \$100,000 and \$166,000 of related staff costs. As disclosed in the Company's Quarterly Cash Flow Report, payments to related parties and their associates during the quarter totaled \$166,000 for director fees, salaries and superannuation payments.

This announcement has been authorised by the Board of Directors.

By order of the Board.



Marcelo Mora  
Company Secretary

pjn12846

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

#### Name of entity

BIOTRON LIMITED

#### ABN

60 086 399 144

#### Quarter ended (“current quarter”)

31 December 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(100)	(178)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(166)	(305)
(f) administration and corporate costs	(154)	(373)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	4	10
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(416)</b>	<b>(846)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material) Cash Acquired on acquisition of subsidiary	112	112
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>112</b>	<b>112</b>
<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	1,646	1,646
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(201)	(201)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>1,445</b>	<b>1,445</b>
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	502	932
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(416)	(846)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	112	112

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,445	1,445
4.5	Effect of movement in exchange rates on cash held	-	-
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>1,643</b>	<b>1,643</b>

<b>5. Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	1,243	42
5.2	Call deposits	400	460
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>1,643</b>	<b>502</b>

<b>6. Payments to related parties of the entity and their associates</b>		<b>Current quarter \$A'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	166
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

Director fees, salaries and superannuation payments.

**7. Financing facilities**

*Note: the term 'facility' includes all forms of financing arrangements available to the entity.*

*Add notes as necessary for an understanding of the sources of finance available to the entity.*

- 7.1 Loan facilities
- 7.2 Credit standby arrangements
- 7.3 Other (please specify)
- 7.4 **Total financing facilities**

<b>Total facility amount at quarter end</b> <b>\$A'500</b>	<b>Amount drawn at quarter end</b> <b>\$A'500</b>
-	-
-	-
-	-
-	-

**7.5 Unused financing facilities available at quarter end**

-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

**8. Estimated cash available for future operating activities**

**\$A'000**

8.1	Net cash from / (used in) operating activities (item 1.9)	(416)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,643
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	1,643
8.5	<b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	3.95

*Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.*

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps, and how likely does it believe that they will be successful?

Answer

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

## **Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 29 January 2026.

Authorised by: By the Board.  
(Name of body or officer authorising release – see note 4)

### **Notes**

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.